✔️#AFIJI Cohort 20 year-follow-up: fal.cn/34s2J @ActionCoeur
✔️ Editorial: fal.cn/34s2K by @ErinMichos and @AChoiHeart
![](https://pbs.twimg.com/media/EGrgWlSX4AA0GXx.jpg)
Arora, et al @CircAHA: fal.cn/34s2N
![](https://pbs.twimg.com/media/EGrh1HxX0AQVmjg.png)
![](https://pbs.twimg.com/media/EGrijOqWsAEEaVD.png)
1⃣: Evaluate the rate of first recurrent MACE and associated risk factors
2⃣: Determine the relationship b/w the initial lesion and the new lesions
3⃣: Determine the rate of repeated recurrences
![](https://pbs.twimg.com/media/EGrkV4KX4AgNqhU.png)
✔️Recurrence rates high despite medical Rx
✔️Recurrent events generally occurred from new coronary lesions (non-obstructive plaques that progressed)
✔️48% with 1st recurrence not taking high-intensity statin
fal.cn/34s3H
![](https://pbs.twimg.com/media/EGrlEh5X0AQAUvp.png)
✔️Factors associated w recurrence: insufficient control of conventional risk factors, multivessel disease, Sub-Saharan African ethnicity & inflammatory disease.
🚬Smoking was strongest modifiable risk factor
fal.cn/34s3H
![](https://pbs.twimg.com/media/EGrl4_iWkAMcP-l.png)
✔️Team-based and pt-centered to better implant guideline care
✔️Consider ezetimibe if LDL > 70 despite max statin
✔️Direct efforts to #cvPrev as per @ACCinTouch /@American_Heart 2019 guidelines. fal.cn/34s3V
![](https://pbs.twimg.com/media/EGrm-s_WsAAfeX7.png)
![](https://pbs.twimg.com/media/EGrn8OtXkAAuu34.png)
![](https://pbs.twimg.com/media/EGropVWXUAI4qCN.png)
![](https://pbs.twimg.com/media/EGrpPiaWoAAu-TP.png)
![](https://pbs.twimg.com/media/EGrp2idW4AAAZ08.jpg)